Labatec Gets Approval To Market Futura’s Eroxon Erectile Dysfunction Gel In Saudi Arabia

Futura Medical's MED3000 erectile dysfunction gel gets OTC approval in the Kingdom of Saudi Arabia, where Switzerland's Labatec Pharma has the rights to commercialize the product under the Eroxon brand. 

Launch
• Source: Shutterstock

Switzerland’s Labatec Pharma SA has received regulatory approval to market Futura Medical plc’s drug-free erectile dysfunction gel MED3000 in the Kingdom of Saudi Arabia.

One of the top ten ED markets in the world by value, according to IQVIA, Saudi Arabia will see the...

More from Marketing & Advertising

Scope Launches Eyelid-Friendly Eye Cream In The UK

 
• By 

Eyelids have the "thinnest, most sensitive skin on the body" and are "highly prone to dehydration," which is why Scope has launched new Optase Life Sensitive Eye Daily Renewal Cream.

P&G’s Crest Gum Detoxify Ad Claims Rinsed Clean In NAD Review On GuruNanda Challenge

 

P&G provided sufficient support for all challenged claims, including the “Gum Detoxify” brand used on the product label and in advertising on the website and in magazine detail pages.

German Associations Call For EU Green Claims Directive Trilogue Suspension

 
• By 

Pharma Deutschland is one of 21 German associations calling for trilogue negotiations in relation to the EU Green Claims Directive to be suspended while a “comprehensive and independent written impact assessment” is undertaken.

TheraBreath ‘Guarantee Better’ Claim Serious, Not Puffery With Founder Prominent In Advertising

 

Challenged advertising, which appeared in a TV commercial, in-store displays and advertising on social media, included express claims “It’s a better mouthwash. I guarantee it.” and “I guarantee it. – ‘Dr. Harold Katz.’”

More from Business

Private Label ‘Smart Imitation’ Of National Brands’ Packaging Not So Wise In US OTC Drug Sector

 

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By 

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.